|1.||Fung, Kwok-Pui: 9 articles (10/2013 - 01/2006)|
|2.||Tang, Patrick Ming-Kuen: 8 articles (01/2011 - 01/2006)|
|3.||Yoon, Jung-Hoon: 5 articles (04/2015 - 09/2011)|
|4.||Kim, Yong-Chul: 5 articles (04/2015 - 09/2011)|
|5.||Rapozzi, Valentina: 5 articles (02/2015 - 07/2009)|
|6.||Chan, Judy Yuet-Wa: 5 articles (10/2013 - 01/2006)|
|7.||Fong, Wing-Ping: 5 articles (04/2010 - 09/2006)|
|8.||Weiss, Johanna: 4 articles (11/2015 - 04/2011)|
|9.||Yoon, Hyo-Eun: 4 articles (04/2015 - 09/2011)|
|10.||Tsui, Stephen Kwok-Wing: 4 articles (01/2009 - 01/2006)|
11/30/2015 - "We focused our interest on an amphiphilic photosensitizer studied for photodynamic treatments of cancer, Pheophorbide-a (Pheo). "
04/01/2015 - "The cellular uptake of pheophorbide-a conjugates in cancer cells overexpressing the corresponding receptors of the targeting moieties was largely enhanced compared with that in the receptor-negative cells. "
04/01/2015 - "Pheophorbide-a conjugates with cancer-targeting moieties for targeted photodynamic cancer therapy."
04/14/2014 - "Lastly, the photodynamic activity was assessed in the presence of pheophorbide a as photosensitizer on 2D and 3D tumor cell culture models, which revealed activity differences between the 2D and 3D systems. "
09/01/2013 - "These results show that Zn-pheophorbide a is a very promising low-cost, synthetically easily accessible, second generation photosensitizer against human cancer."
|2.||Phototoxic Dermatitis (Phototoxicity)
12/01/1988 - "Studies on photodynamic action of chlorophyl derivatives--phototoxicity of pheophorbide-A on rats."
07/17/2009 - "Intracellular uptake and phototoxicity of pheophorbide a as well as of the Pheo-HSA nanoparticles were studied in Jurkat cells. "
09/01/2011 - "To evaluate the efficacy of compound 1 as a photosensitizer for head and neck cancers, compound 1 was studied in reference to a known photosensitizer pheophorbide-a (Pha), in terms of photophysical properties, singlet oxygen generation and in in vitro experiments (intracellular uptake and phototoxicity assays) in two oral (HSC2 and HSC3) and two nasopharyngeal (HK1 and C666-1) cancer cell lines. "
08/01/2010 - "Self-quenching polysaccharide-based nanogels synthesized from pullulan/folate-pheophorbide-a (Pheo-A) conjugates were investigated for their potential to reduce photosensitizer (PS) phototoxicity in normal tissue and to enhance the efficacy of tumor treatment. "
|3.||Breast Neoplasms (Breast Cancer)
11/01/2006 - "Synthesis of estradiol-pheophorbide a conjugates: evidence of nuclear targeting, DNA damage and improved photodynamic activity in human breast cancer and vascular endothelial cells."
05/01/2013 - "The following were evaluated: P-glycoprotein (P-gp/ABCB1) inhibition by calcein assay; breast cancer resistance protein (BCRP/ABCG2) inhibition by pheophorbide A efflux; and inhibition of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 by 8-fluorescein-cAMP uptake. "
01/01/2014 - "P-glycoprotein (P-gp, MDR1, ABCB1) inhibition was evaluated by calcein assay, inhibition of breast cancer resistance protein (BCRP, ABCG2) by pheophorbide A efflux, and inhibition of organic anion transporting polypeptides (OATPs) by 8-fluorescein-cAMP uptake. "
04/01/2011 - "We evaluated P-glycoprotein (P-gp/ABCB1) inhibition by the calcein assay in P388/dx and L-MDR1 cells, breast cancer resistance protein (BCRP/ABCG2) inhibition in MDCKII-BCRP cells by pheophorbide A efflux, and inhibition of the multidrug resistance-associated protein 2 (MRP2/ABCC2) by using the MRP2 PREDIVEZ™ Vesicular Transport Kit. "
11/01/2015 - "Obatoclax was screened for P-gp inhibition by calcein assay, for breast cancer resistance protein (BCRP) inhibition by pheophorbide A assay and for inhibition of cytochrome P450 isoenzymes (CYPs) by commercial kits. "
|5.||Colonic Neoplasms (Colon Cancer)
|2.||Folic Acid (Vitamin M)
|3.||Dihematoporphyrin Ether (Porfimer Sodium)
|9.||Photosensitizing Agents (Photosensitizers)
|1.||Photochemotherapy (Photodynamic Therapy)
|3.||East Asian Traditional Medicine (Oriental Medicine)